Document Title: Adverse Event Reporting
|
|
- Claud Whitehead
- 7 years ago
- Views:
Transcription
1 Document Title: Adverse Event Reporting Document Number: SOP012 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D Administration Manager, Research Officers R&D Administration Manager Research and Development Research and Development NHS Staff Trust-Wide Review due: April 2016 THIS IS A CONTROLLED DOCUMENT Whilst this document may be printed, the electronic version maintained on the Trust s Intranet is the controlled copy. Any printed copies of this document are not controlled. Papworth Hospital NHS Foundation Trust. Not to be reproduced without written permission. Key Points of this Document This document sets out the procedures to be followed by all Papworth Staff who are involved in the reporting of adverse events in clinical trials. It aims to provide clear guidance on how to report adverse events and incidents that occur in the course of research studies to ensure compliance with the Trust s policy for the reporting of accidents / adverse events / incidents and defects (DN70). Version 3.2 Review Date: April 2016 Page 1 of 16
2 1 Purpose and Content a. This document defines the Trust s research procedures for the reporting and investigation of any adverse event that occur involving patients in Research Studies and Clinical Trials sponsored by Papworth Hospital s R&D department. This includes the completion of Adverse Event forms. b. In accordance with the Research Governance Framework for Health and Social Care and the Medicines for Human Use (Clinical Trials) Regulations, organisations hosting and Sponsoring research must have systems in place that allow to give the safety of participants and of research and other staff priority at all times, and [ensure that] health and safety regulations [are] strictly observed including the provision of information, containment, shielding and monitoring as required. c. The Medicines for Human Use (Clinical Trials) Regulations 2004 came into force on the 1st May These regulations apply to all clinical trials involving investigational medicinal products (IMPs) and specify the reporting requirements for related adverse events. To breach these requirements constitutes a breach in criminal law. These reporting requirements have been incorporated within this policy. d. This SOP covers the recording and reporting of Research Related Adverse Events, including Adverse Reactions, Adverse Device Effects, Serious Adverse Events, Serious Adverse Reactions, Serious Adverse Device Effects, Suspected Unexpected Serious Adverse Reactions and Unanticipated Serious Adverse Device Effects. These adverse events will be managed in line with the reporting policy of the Sponsor of a research study. e. The reporting requirements in this SOP are mandatory in addition to the Trust s policy for the reporting of accidents / adverse events / incidents and defects (DN70) and noncompliance with may result in disciplinary procedures. 2 Roles & Responsibilities 2.1 Roles a. All staff are responsible for ensuring that all adverse incidents, whether or not related to research, are reported in accordance with the Papworth Hospital NHS Trust s policy for the reporting of accidents / adverse events / incidents and defects (DN70). b. This Procedure applies to all personnel that are conducting research at the Trust. Version 3.2 Review Date: April 2016 Page 2 of 16
3 c. Staff involved in the conduct of CTIMPs must comply with the requirements set out in this SOP. d. Flow diagrams that summarise the investigator s and sponsor s responsibilities for reporting adverse events are available from the Papworth R&D department. 2.2 Investigators responsibilities a. The investigator must ensure that the dignity, rights, safety and well being of research participants are given priority at all times and must take appropriate action to ensure the safety of all staff and participants in the study. The investigator will consider what actions, if any, are required and in what timeframe following the requirements set in this policy. b. In the event of an adverse event / reaction (AEs) the investigator (or delegate) must review all the documentation that is relevant to the event (e.g. patient notes, laboratory reports). The event and relevant comments must be recorded in the subject s medical notes (or source data) and reported to the Sponsor as documented in the protocol. Investigators (or delegated persons) will provide follow-up information, each time new information is available using the study CRF provided or page 3 of the form entitled FRM007 Papworth SAE/SUSAR Reporting Form (available from the R&D intranet pages). This will be completed until the SAE / SADE has resolved or a decision for no further follow-up has been taken by the PI or delegated person. c. Unless the protocol states otherwise and has exempted certain events from being recorded or escalated reporting, the Investigator (or delegate) is responsible for ensuring that all adverse event / reactions are recorded in detail on case report forms or equivalent so as to allow analysis at a later stage. A template for recording adverse events can be found on the R&D intranet pages entitled FRM005 Adverse Event/Adverse Reaction Reporting Form). d. The investigator (or delegate) will make an assessment of causality for all adverse event / reactions. This process must be clearly documented. This must be completed by medically qualified personnel. Detailed guidance on making this assessment is given in the Appendix 1. A short assessment for the internal purposes of the research team is provided in the form Version 3.2 Review Date: April 2016 Page 3 of 16
4 entitled FRM005 Adverse Event/Adverse Reaction Reporting Form. e. The Investigator (or delegate) must ensure that Adverse Events and / or laboratory abnormalities identified in the protocol as critical to the evaluations of the safety of the study shall be reported to the Sponsor in accordance with the reporting requirements documented in the protocol. f. The chief investigator will keep the Sponsor, the REC and MHRA (if applicable) informed of any significant findings and recommendations by an independent Data Monitoring Committee (DMC), or equivalent, where one has been established for the trial. 2.3 Sponsor responsibilities a. This section applies only where Papworth R&D is the sponsor or co-sponsor of the research study A flow diagram summarising the R&D department s responsibilities for adverse event reporting is available from Papworth R&D department upon request. b. The Senior Manager, or their delegated representative, must keep a detailed record of all AEs relating to all clinical trial that are reported to it and ensure that system is in place for ensuring appropriate follow-up of SAEs. On receipt of a SAE / SUSAR report form the Senior Manager will assess whether Papworth R&D is the sponsor. Where Papworth R&D is NOT the sponsor or cosponsor the Senior Manager will remind the research team to inform the sponsor. c. The Senior Manager, or their delegated representative, must ensure that cover will be provided for the fax machine used for sending in adverse event reports to ensure events are processed in a timely manner (which includes holiday periods). d. The Senior Manager, or their delegated representative, is responsible for the assessment of expectedness of adverse events. This responsibility may be delegated the chief investigator. This delegation must be clearly documented. Version 3.2 Review Date: April 2016 Page 4 of 16
5 2.4 For Blinded Studies: a. Where Papworth R&D is the sponsor or cosponsor of a blinded research study, in which the SAE / SUSAR / SADE / USADE has occurred, and a member of the research team is unable to make a blinded assessment, the Senior Manager, or their delegated representative, will make an unblinded assessment of the intensity, causality, expectedness and seriousness using the criteria described in this policy. b. In making this assessment the Senior Manager, or their delegated representative, will consult the independent Data Monitoring Committee (DMC) for the study or, where a DMC does not exist, a suitably qualified medical person. The unblinded assessor may be an investigator on the same study if unblinding him / her will not affect the conduct of the study in which the SAE has occurred. c. A second assessment by the Sponsor is not required where the investigator making the initial assessment is already unblinded. d. A clear procedure must be detailed in the protocol for Papworth sponsored CTIMPs. e. The Senior Manager, or their delegated representative, will consider whether any further actions following an adverse event, in addition to those already taken by the Investigator, are required and will discuss these with the Investigator. f. The Senior Manager, on behalf of the Trust, reserves the right to suspend or withdraw approval for a study. This may happen, but is not limited to, where public health and safety is considered to be at risk, where the safety and well being of research subjects or staff are considered to be at risk. g. The sponsor is responsible for ensuring that actions that necessitate a substantial amendment to the research protocol will be approved by ethical, R&D and MHRA (for IMP and non CE marked devices) through the normal routes. See SOP037 Amendments Post Trust Approval for further information. This duty may be delegated to the Chief Investigator. h. Amendments that require an immediate change to the protocol (i.e. urgent safety measures) will be implemented and thereafter submitted for ethical, R&D and MHRA approval. The initial notification to the REC should be by telephone. Notice in writing to the REC, hosting R&D and MHRA should be sent within three days. The notice should set out the reasons for the urgent safety measures and plan for further action. i. The Sponsor is responsible for ensuring that at the conclusion of the study all adverse events / reactions / device effects, recorded during a study are subject to statistical analysis and that analysis and subsequent conclusions included in the final study report. Version 3.2 Review Date: April 2016 Page 5 of 16
6 3 Definitions AE Adverse Event - any untoward medical occurrence in a subject to whom a medicinal product / medicinal device / intervention has been administered, including occurrences which are not necessarily caused or related to the product. AR Adverse Reaction - any untoward and unintended response in a subject to an investigational medicinal product / medicinal device / intervention that is related to any dose administered to that patient. ADE Adverse Device Event - any malfunction or deterioration in the characteristics and / or performance of a device, as well as any inadequacy in the labelling or the instructions for use that might lead, or might have led to, endangering the health of a patient or the device user. An unexpected adverse reaction is an adverse reaction the nature and severity of which is not consistent with the information about the medicinal product or intervention in question set out: in the case of a product with a marketing authorisation, in the Summary of Product Characteristics (SmPC) for that product in the case of any other investigational medicinal product, in the Investigators Brochure (IB) SAE /SADE / SAR SAE SADE An adverse event, adverse reaction, unexpected adverse reaction, adverse device effect is defined as serious if it: results in death is life-threatening requires hospitalisation or prolongation of existing hospitalisation results in persistent or significant disability or incapacity consists of a congenital anomaly or birth defect Serious Adverse Event Serious Adverse Device Event Version 3.2 Review Date: April 2016 Page 6 of 16
7 SAR SUSAR Serious Adverse Reaction Suspected Unexpected Serious Adverse Reaction - is an SAR that is suspected (possibly of probably) to be related to the investigational medicinal product / medicinal device / intervention AND is also unexpected. This means that its nature and severity are not consistent with the information about the medicinal product in question set out as below: in the case of a product with a marketing authorisation, in the Summary of Product Characteristics (SmPC) for that product in the case of any other investigational medicinal product, in the Investigators Brochure (IB) A non-imp SUSAR is an SAE that occurs in a non-imp trial and is: Related that is possibly, probably or definitely resulted from administration of any of the research procedures, and Unexpected that is, the type of event is not listed in the protocol as an expected occurrence USADE Unanticipated Serious Adverse Device Effect - an untoward medical occurrence that happens in a subject or other person that is related to the investigational device, device procedure or comparator, which is serious and was unanticipated. 4 Procedure If a participant is participating in a randomised clinical trial the reporting must be carried out according to this SOP irrespective of the arm of the trial the patient is in. 4.1 Reporting of Serious Adverse Events / Serious Adverse Device Effects a. Researchers must ensure that all patient safety related incidents are reported according to the Trust s policy for the reporting of accidents / adverse events / incidents and defects (DN70). b. In addition to the Trust s incident reporting, serious adverse events must be reported as per Table 1. The only exception is where the protocol or Investigators Brochure identifies an event as not requiring immediate expedited reporting. Table 1 Report to Investigator Responsibilities SUSAR / USADE Immediately report to: The investigator (or delegated person) will make an initial report, orally or in writing, within 24 hours of Version 3.2 Review Date: April 2016 Page 7 of 16
8 The Chief Investigator The Sponsor knowledge of the event. The initial report will include as much information as is available at the time. Papworth department R&D Oral reports will be followed up in writing within a further 24 hours of the initial report. Papworth Clinical Governance and Risk Management Any other persons or bodies specified in the protocol Sponsor responsible to further expedite the reporting of SUSAR / USADE to the MHRA and REC that gave approval as soon as possible but within 7 days of knowledge of the event. After the initial report the investigator is required to actively follow up the subject. The investigator (or delegated person) will provide information missing from the initial report within five working days of the initial report. Written reports will be made by completing an SAE / SUSAR reporting form provided by the Sponsor of the study. In addition the REC receives a completed NRES CTIMP Safety Report to REC Papworth R&D SAE / SAR / SUSAR report template entitled FRM007 SAE/SAR/SUSAR Reporting Form v1.0 is available from the Research Department Where Papworth is the sponsor or co-sponsor or where no form has been provided, the investigator will use the standard Research Related SAE/SUSAR form entitled FRM007 SAE/SAR/SUSAR Reporting Form v1.0 that is available from R&D. Only one report will need to be sent to Papworth R&D department. SAE / SADE Within 24 hours report to: The Chief Investigator The Sponsor Any other persons or bodies specified in the protocol As above; but no expedited reporting by the Sponsor to the MHRA and REC. Version 3.2 Review Date: April 2016 Page 8 of 16
9 For Papworth Sponsored CTIMPs and non-ce marked devices also contact the R&D department. Urgent Safety Measures / Temporary Halt of a Trial Implement and report immediately as a substantial amendment to: The Chief Investigator The Sponsor The Chief Investigator must inform as soon as possible, but within 3 days: The MHRA The REC that gave approval Any other persons or bodies specified in the protocol Papworth R&D department The Sponsor and the Chief Investigator must be notified of any urgent safety measures / temporary halt of a trial that have had to be taken that are not part of the protocol. The report must include the reasons for the urgent safety measure and the plan for further action. The standard CTIMP substantial amendment form must be used as available from MHRA / NRES websites. Where Papworth R&D is the Sponsor (or Cosponsor) and the host organisation only one report needs to be sent to the R&D department. 4.2 For Papworth Sponsored Studies a. The Chief Investigator will inform all Principal Investigators of relevant information about SAEs / SADEs that could adversely affect the safety of subjects. b. The Chief Investigator will provide the main REC with copies of all reports and recommendations of any independent Data Monitoring Committee established for a trial as part of the SUSAR / USADE expedited or periodic reporting. Version 3.2 Review Date: April 2016 Page 9 of 16
10 c. For IMP / Medical Device studies, on request of the MHRA the Chief Investigator will submit detailed records of all adverse events that have been reported. 4.3 IMP SUSARs a. This section applies only where Papworth R&D is the sponsor or cosponsor of the research study using an IMP in which the SAE has occurred and where the investigator and / or sponsor has assessed the SAE to be a SUSAR. b. The R&D Department as the Sponsor s representative will report all SUSARs to: The Medicines and Healthcare Regulatory Agency (MHRA) The competent authorities (equivalent of the MHRA) of any EEA State, other than the UK, in which the trial is being conducted The REC that granted approval c. Papworth R&D will report within seven days of becoming aware of the event where these are fatal or life threatening and within fifteen days where the SUSAR was not assessed as life threatening or fatal. d. The R&D Department will report any additional relevant information to the bodies described above within eight days of the last report. e. Initial notifications of SUSARs may be made by fax, or telephone. Follow-up reports and all other safety reports should be sent to the REC office by post. f. Each submission of a SUSAR Sponsor report form to the main REC must be accompanied by the NRES Safety Report form for CTIMPs available at mailto: g. A single form may be used for the submission of several safety reports relating to the same trial. Reports should not normally cover more than one trial. However, the REC may permit this where two trials are very closely connected such as a main study and an extension study with the same treatment regime. 4.4 Non-IMP SUSARs a. Where Papworth R&D is the sponsor or cosponsor of a blinded non-imp study, the R&D department will report all SAEs that are assessed as non-imp SUSARs by either the investigator or the unblinded assessor to the research ethics committee that granted approval within 15 days using the NRES Report of Serious Adverse Event form available Version 3.2 Review Date: April 2016 Page 10 of 16
11 at: mailto: b. Follow-up of pregnancy within CTIMPs c. Pregnancy does not meet the definition of an SAE, but a congenital abnormality or birth defect is classed as an SAE. d. For all CTIMPs, if a pregnancy occurs either in a female subject or the female partner of a male subject the pregnancy should be followed up until at least the end of the pregnancy. e. The investigator is responsible for notifying the sponsor as soon as they become aware of a pregnancy. f. The Investigator must obtain informed consent for follow-up of the pregnancy from the trial subject (or their partner in the case of male subjects). g. Following the end of the pregnancy an SAE form must be completed if there is a congenital abnormality or birth defect. 4.5 Annual Safety, Annual Progress and End of Study Reports a. Where Papworth R&D is the sponsor or cosponsor, at the request of the Chief Investigator, the R&D department will assist the Chief Investigator in compiling the Annual Safety, Annual Progress and End of Study Reports. See SOP062 Preparation of Development Safety Update Reports. b. In meeting such requests the R&D Department will take all reasonable efforts to ensure that no information that could unblind and therefore compromise the study is provided directly to the Chief Investigator, unless the Chief Investigator is already unblinded. 5 Risk Management / Liability / Monitoring & Audit a. The R&D SOP Committee will ensure that this SOP and any future changes to this document are adequately disseminated. b. The R&D Department will monitor adherence to this SOP via the routine audit and monitoring of individual clinical trials and the Trust s auditors will monitor this SOP as part of their audit of Research Governance. From time to time, the SOP may also be inspected by external regulatory agencies (e.g. Care Quality Commission, Medicines and Healthcare Regulatory Agency). c. In exceptional circumstances it might be necessary to deviate from this SOP for which written approval of the Senior R&D Manager should be gained before any action is taken. SOP deviations should be recorded including details of alternative procedures followed and filed in the Investigator and Sponsor Master File. Version 3.2 Review Date: April 2016 Page 11 of 16
12 d. The Research and Development Directorate is responsible for the ratification of this procedure. Version 3.2 Review Date: April 2016 Page 12 of 16
13 Appendix 1: Assessment of Adverse Events Intensity The assessment of intensity will be based on the investigator s clinical judgement using the following definitions: Mild: An event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities Moderate: An event that is sufficiently discomforting to interfere with normal everyday activities Severe: An event that prevents normal everyday activities Causality The relationship between the drug / device / procedure and the occurrence of each adverse event will be assessed and categorised as below. The investigator will use clinical judgement to determine the relationship. Alternative causes, such as natural history of the underlying diseases, concomitant therapy, other risk factors etc., will be considered. The Investigator will also consult the Investigators Brochure or other product information. Not related: Temporal relationship of the onset of the event, relative to administration of the product, is not reasonable or another cause can by itself explain the occurrence of the event. Unlikely: Temporal relationship of the onset of the event, relative to administration of the product, is likely to have another cause that can by itself explain the occurrence of the event. Possibly related: Temporal relationship of the onset of the event, relative to administration of the product, is reasonable and the event could have been due to another, equally likely cause. Probably related: Temporal relationship of the onset of the event, relative to administration of the product, is reasonable and the event is more likely explained by the product than any other cause. Definitely related: Temporal relationship of the onset of the event, relative to administration of the product, is reasonable and there is no other cause to explain the event, or a re-challenge (if feasible) is positive. Where an event is assessed as possibly related, probably related, definitely related the event is an adverse reaction. Version 3.2 Review Date: April 2016 Page 13 of 16
14 Diagram depicting how Causality determines what is an event and what is a reaction. Expectedness Adverse reactions must be considered as unexpected if they add significant information on the specificity or severity of an expected adverse reaction. The expectedness of an adverse reaction shall be determined according to the reference documents as defined in the study protocol (e.g. investigator brochure or marketing information). For Papworth Sponsored studies all expected events must be listed in the protocol. Expected: Reaction previously identified and described in the protocol or reference documents e.g. Investigator Brochure (IB) or Summary of Product Characteristics (SmPC). Unexpected: Reaction not previously described in the protocol or reference documents. NB the protocol must identify the reference documentation used. Seriousness An event is considered serious if it meets one or more of the following criteria: Results in death Is life-threatening Requires hospitalisation or prolongation of existing hospitalisation Results in persistent or significant disability or incapacity Consists of a congenital anomaly or birth defect Further Document Information Version 3.2 Review Date: April 2016 Page 14 of 16
15 Approved by: Management/Clinical Directorate Group Approval date: (this version) Ratified by Board of Directors/ Committee of the Board of Directors: Date: Research and Development Directorate 13 th June 2013 (Chairman s action) STET N/A Medicines for Human Use (Clinical Trials) Regulations 2004 and all associated amendments. Research Governance Framework for Health and Social Care (2005) This document supports: Standards and legislation Key related documents: EN ISO 14155: 2011 Clinical Investigations of medical devices for human subjects Good Clinical Practice ISO/TS :2011 Medical Devices Hierarchical coding structure for adverse events Part 1: Event type codes EN ISO 14971: 2007 Medical Devices Application of risk management to medical devices Trust Research Policy Research and Development Standard Operating Procedures entitled: SOP019 Research Protocol SOP037 Substantial Protocol Amendment SOP062 Preparation of Development Safety Update Reports. Trust s policy for the reporting of accidents / adverse events / incidents and defects (DN70) Equality Impact Assessment: Does this document impact on any of the following groups? If YES, state positive or negative, complete Equality Impact Assessment Form available in Disability Equality Scheme document DN192 and attach. Groups Disability Race Gender Age Sexual orientation Religious & belief Other Yes/No No No No No No No No Positive/Negative Review date: April 2016 Version Control Version 3.2 Review Date: April 2016 Page 15 of 16
16 Version Date effective Valid to Approved by Date of approval 1.0 July 2011 RDD 5 th August th February 2012 February 2014 RDD 10 th February nd August 2013 April 2016 RDD (chairman s action) 13 th June th February 2015 April 2016 HRA link updated th May 2015 April 2016 Formatting updated 4.0 Version 3.2 Review Date: April 2016 Page 16 of 16
R&D Administration Manager. Research and Development. Research and Development
Document Title: Document Number: Patient Recruitment SOP031 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D Administration Manager,
More informationDocument Title: Project Management of Papworth Sponsored Studies
Document Title: Project Management of Papworth Sponsored Studies Document Number: SOP009 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G
More informationDocument Title: Trust Approval and Research Governance
Document Title: Trust Approval and Research Governance Document Number: SOP034 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D
More informationDocument Title: Research Database Application (ReDA)
Document Title: Research Database Application (ReDA) Document Number: SOP035 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D
More informationDocument Title: Supply of Clinical Trials Investigational Material: Dispensing, Returns and Accountability
Document Title: Supply of Clinical Trials Investigational Material: Document Number: SOP072 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G
More informationStandard Operating Procedures (SOP) for: Reporting of Serious Breaches of GCP or the Trial Protocol sponsored CTIMP s. Lisa Austin, Research Manager
Standard Operating Procedures (SOP) for: Reporting of Serious Breaches of GCP or the Trial Protocol sponsored CTIMP s Author: Lisa Austin, Research Manager Purpose and Objective: To identify and standardise
More informationSTANDARD OPERATING PROCEDURE FOR RESEARCH. 2. Notification of Serious Breaches of Good Clinical Practice or Study Protocol
Basildon and Thurrock University Hospitals NHS FT Research & Development APPROVED STANDARD OPERATING PROCEDURE FOR RESEARCH 2. Notification of Serious Breaches of Good Clinical Practice or Study Protocol
More informationCONTENTS SECTION TITLE PAGE
CONTENTS SECTION TITLE PAGE 1 Introduction 3 2 Scope 3 3 Abbreviations 4 4 Definitions 4 4.1 Medical device 4 4.2 Investigational medical device 4 4.3 Adverse event 5 4.4 Intensity 5 4.5 Serious adverse
More informationST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014
ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014 1. Introduction The St. Michael s Hospital (SMH) REB
More informationStandard Operating Procedure on Training Requirements for staff participating in CTIMPs Sponsored by UCL
Page 1 of 10 Standard Operating Procedure on Training Requirements for staff participating in CTIMPs Sponsored by UCL SOP ID Number: Effective Date:01/08/2012 Version Number & Date of Authorisation: V02,
More informationStandard Operating Procedure for the Recording, Management and Reporting of Adverse Events by Investigators
ASR\INV_S05_SOP for AE_SAE_Reporting by Inv_V06.doc Page 1 of 19 Standard Operating Procedure for the Recording, Management and Reporting of Adverse Events by Investigators SOP Number: Effective Date:
More informationClinical trials: from European perspective to National implementation. CTFG / FAMHP / pharma.be. Brussels, 19 November 2010
Clinical trials: from European perspective to National implementation CTFG / FAMHP / pharma.be Brussels, 19 November 2010 Safety in clinical trials: From detection to decision How safety events are captured
More informationGUIDELINES ON MEDICAL DEVICES
EUROPEAN COMMISSION DG Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Health technology and Cosmetics MEDDEV 2.7/3 revision 3 May 2015 GUIDELINES ON
More informationROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS
ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS STANDARD OPERATING PROCEDURE NO SOP 09 DATE RATIFIED 4/7/13 NEXT REVIEW DATE 4/7/14 POLICY STATEMENT/KEY OBJECTIVES:
More informationSerious Breaches. Ian Gravenor. Senior Clinical Project Manager Novo Nordisk Ltd
Serious Breaches Ian Gravenor Senior Clinical Project Manager Novo Nordisk Ltd Serious Breaches of GCP or the Trial Protocol Agenda Why report? The legislation MHRA Guidance document Timelines Actions
More informationStandard Operating Procedures (SOP) Research and Development Office
Standard Operating Procedures (SOP) Research and Development Office Title of SOP: Undertaking Risk Assessment of a Research and Development Project SOP Number: 33 Version Number: 1.0 Supercedes: N/A Effective
More informationGENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):
Make copies of the blank SAE report form as needed. Retain originals with confirmation of all information faxed to DMID Pharmacovigilance Group Clinical Research Operations and Management Support (CROMS
More informationPHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE
PHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE PART A: TRIAL INFORMATION A1. Title of Clinical Trial (as stated in proposed Protocol) Protocol No.
More informationTRIAL MASTER FILE- SPONSORED
gsop-06-04 - Management of TMF for ENHT/ WHHT Sponsored CTIMPs Page 1 of 16 Hertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust TRIAL MASTER
More informationMarie-Claire Rickard, GCP & Governance Manager Rachel Fay, GCP & Governance Manager Elizabeth Clough, R&D Operations Manager
Standard Operating Procedures (SOP) for: Monitoring SOP 28 Version 7.0 Number: Number: Effective Date: 29 th November 2015 Review Date: 6 th January 2017 Author: Reviewer: Reviewer: Authorisation: Name
More informationDESCRIPTION OF THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004
DESCRIPTION OF THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 Page 1 of 17 TABLE OF CONTENTS INTRODUCTION 4 EXECUTIVE SUMMARY 4 PUBLIC HEALTH BENEFITS 5 Good clinical practice 5 Good manufacturing
More informationTEMPLATE DATA MANAGEMENT PLAN
TEMPLATE DATA MANAGEMENT PLAN ICRIN (QM sub group) Version: XX Date: XXXXXXX Page 1 of 6 1.0 Document Ownership The Data Management Plan (DMP) will be initiated and subsequently owned by the Data Manager
More informationGuidance notes. for Patient Safety and Pharmacovigilance in Patient Support Programmes
Guidance notes for Patient Safety and Pharmacovigilance in Patient Support Programmes 9 May 2011 Approval Status Authors The ABPI Pharmacovigilance Expert Network Change History N/A Approval Date 9 May
More informationArchiving of Research Documentation
Suspension, Termination & Completion Standard Operating Procedure VERSION / REVISION: 2.0 EFFECTIVE DATE: 28 05 12 REVIEW DATE: 28 05 14 AUTHOR(S): CONTROLLER: APPROVED BY: Clinical Trials Manager; Recruitment
More informationCONTROLLED DOCUMENT- DO NOT COPY STANDARD OPERATING PROCEDURE. STH Investigator
Research Department STANDARD OPERATING PROCEDURE STH Investigator Archiving of Essential Documentation Generated During Clinical Research SOP Number A127 Version Number V1.3 Effective Date Author Zoe Whiteley
More informationJoint Research Office
Office Location: 1 st Floor Maple House 149 Tottenham Court Road London W1T 7DN Joint Research Office Postal Address: UCL, Gower Street London WC1E 6BT Email: hameedah.bogle-dawoud@nhs.net Tel No. 020
More informationBurton Hospitals NHS Foundation Trust. Committee On: 19 May 2015. Review Date: March 2018. Corporate / Directorate
POLICY DOCUMENT Burton Hospitals NHS Foundation Trust RESEARCH GOVERNANCE AND INNOVATION POLICY Approved by: Executive Management Committee On: 19 May 2015 Review Date: March 2018 Corporate / Directorate
More informationDorset Research Consortium. Research Governance: A handbook for Researchers in Dorset
Dorset Research Consortium Research Governance: A handbook for Researchers in Dorset DRC Version 1 dated 25 th July 2012 Research Governance: The Basics... 4 What is Research Governance?... 4 The Research
More informationClinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity
Clinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity Michelle Quaye Regulatory Manager, Advanced Therapy Trials University College London Overview The Principles of Good
More informationLaurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute
Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute Understand the protocol completely Recognize institutional polices
More informationSummary of the role and operation of NHS Research Management Offices in England
Summary of the role and operation of NHS Research Management Offices in England The purpose of this document is to clearly explain, at the operational level, the activities undertaken by NHS R&D Offices
More informationIOWA STATE UNIVERSITY Institutional Review Board. Reporting Adverse Events and Unanticipated Problems Involving Risks to Subjects or Others
IOWA STATE UNIVERSITY Institutional Review Board Reporting Adverse Events and Unanticipated Problems Involving Risks to Subjects or Others Introduction This policy details the Institutional Review Board
More informationgsop-32-02 - Vendor Assessment SOP page 1 of 10
gsop-32-02 - Vendor Assessment SOP page 1 of 10 Hertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust VENDOR ASSESSMENT Research & Development
More informationHaving regard to the Treaty establishing the European Community, and in particular Article 95 thereof,
L 121/34 DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to
More informationHuman Research Protection Program Good Clinical Practice Guidance for Investigators Investigator & Research Staff Responsibilities
This Guidance Document is to ensure that investigators and research personnel recognize their responsibilities associated with the conduct of human subject research by outlining their responsibilities,
More informationSouth West Lincolnshire NHS Clinical Commissioning Group Business Continuity Policy
South West Lincolnshire NHS Clinical Commissioning Group Business Continuity Policy Reference No: CG 01 Version: Version 1 Approval date 18 December 2013 Date ratified: 18 December 2013 Name of Author
More informationManaging Risk in Clinical Research. Dr Martha J Wrigley R&D Manager Senior Visiting Fellow University of Surrey
Managing Risk in Clinical Research Dr Martha J Wrigley R&D Manager Senior Visiting Fellow University of Surrey Aim of the session To explore the risks associated with clinical research and understand how
More informationAdverse Events in Clinical Trials: Definitions and Documentation
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators Adverse Events in Clinical Trials: Definitions
More informationThis document is meant purely as a documentation tool and the institutions do not assume any liability for its contents
2001L0020 EN 07.08.2009 002.001 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents B DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT
More informationResearch Study Close-down and Archiving Procedures
Title: Outcome Statement: Research Study Close-down and Archiving Procedures To inform researchers of the process for closing down research studies, retaining and storing research materials in the Trust.
More informationICRIN Seminar on EU Regulation of Clinical Trials
ICRIN Seminar on EU Regulation of Clinical Trials 12 th March 2013, Dublin J. Michael Morris Director Scientific Affairs IRISH MEDICINES BOARD 28/03/2013 Slide 1 Overview Clinical Trial (CT) legislation
More informationQuestions and Answers to the Annual Safety Report
Questions and Answers to the Annual Safety Report Frequently asked questions regarding the Development Safety Update Report (DSUR) Question 1 DSUR Start Stop 1.1 When to start preparing and where to submit
More informationThe EU Clinical Trial Regulation A regulator s perspective
5 The EU Clinical Trial A regulator s perspective Author Martyn Ward, Group Manager, Licensing, Medicines and Healthcare products Regulatory Agency (MHRA), UK. Keywords Clinical Trial Directive (the Directive);
More informationUK Implementation of the EU Clinical Trial Directive 2001/20/EC:
UK Implementation of the EU Clinical Trial Directive 2001/20/EC: GCP Aspects. Dr. Colin Wilsher, FRQA. BARQA GCP Committee Chairman; & Pfizer Worldwide Development Quality Assurance. GIQAR, Roma, October
More informationSTANDARD OPERATING PROCEDURE. Risk Assessment of STH sponsored CTIMPs
Research Department STANDARD OPERATING PROCEDURE of STH sponsored CTIMPs SOP History None SOP Number C118 Created STH Research Department (EW) Reviewed STH Research Department (EW) Superseded Version 1.0,
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Denmark
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Denmark Question 1: What laws or regulations apply to an application for conducting a clinical
More informationThe Study Site Master File and Essential Documents
The Study Site Master File and Essential Documents Standard Operating Procedure Office of Health and Medical Research Queensland Health SOP reference: 002 Version number: 1 Effective date: 01 June 2010
More informationSafety Alerts Management Policy
Safety Alerts Management Policy Version Number 1.1 Version Date February 2014 Policy Owner Author First approval or date last reviewed Staff/Groups Consulted Director of Nursing and Clinical Governance
More informationEMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART
EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART Framework Labs generate data that are used to make decisions on the safety and efficacy of medicinal products; consequently,
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 20 February 2012 EMA/876333/2011 3 4 Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions Draft finalised by the Agency in collaboration with Member States 7 February 2012 Definitions
More informationEU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE
EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE Purpose 1. The Clinical Trials Directive 2001/20/EC heralds certain additional responsibilities for the Medicines and Healthcare
More information12.0 Investigator Responsibilities
v. 5.13.13 12.0 Investigator Responsibilities 12.1 Policy Investigators are ultimately responsible for the conduct of research. Research must be conducted according to the signed Investigator statement,
More informationSubject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure
703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a
More informationINFORMATION GOVERNANCE POLICY
INFORMATION GOVERNANCE POLICY Primary Intranet Location Information Management & Governance Version Number Next Review Year Next Review Month 7.0 2018 January Current Author Phil Cottis Author s Job Title
More informationSOP Number: SOP-QA-20 Version No: 1. Author: Date: 1-9-15 (Patricia Burns, Research Governance Manager, University of Aberdeen)
Standard Operating Procedure: SOP Number: SOP-QA-20 Version No: 1 Author: Date: 1-9-15 (Patricia Burns, Research Governance Manager, University of Aberdeen) Approved by: Date: 1-9-15 (Professor Julie Brittenden,
More informationClinical Trials - Insurance and Indemnity
Policy Directive Clinical Trials - Insurance and Indemnity Document Number PD2011_006 Publication date 25-Jan-2011 Functional Sub group Corporate Administration - Governance Clinical/ Patient Services
More informationVersion history Version number Version date Effective date 01 dd-mon-yyyy dd-mon-yyyy 02 dd-mon-yyyy dd-mon-yyyy 03 (current) dd-mon-yyyy dd-mon-yyyy
Trial name: HOVON xxx yyy Sponsor: HOVON Version history Version number Version date Effective date 01 dd-mon-yyyy dd-mon-yyyy 02 dd-mon-yyyy dd-mon-yyyy 03 (current) dd-mon-yyyy dd-mon-yyyy QRMP authors
More informationQuality Monitoring Checklist
Quality Monitoring Checklist Instructions: For each task below, the Quality Monitor indicates in the appropriate column if the Monitor accomplished the task by using the following codes Yes No N/A = Monitor
More informationAct of 26 February 1998, containing rules on medical research involving human subjects (Medical Research (Human Subjects) Act)
[This is an unofficial translation and is provided for reference purposes only. It is not certified and it has not been authorised by the Dutch government; persons using this translation do so entirely
More informationGOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE
ICH E6 GCP: Consolidated Guideline: Investigator 1/7 Institutional Review Board Services ICH HARMONIZED TRIPARTITE GUIDELINE E6: GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE 4. INVESTIGATOR 4.1 Investigator's
More informationSTANDARD OPERATING PROCEDURE FOR RESEARCH. Management of Essential Documents and Trial Folders
STANDARD OPERATING PROCEDURE FOR RESEARCH Management of Essential Documents and Trial Folders Author Linda Ward Author s Job Title QA Coordinator Division Department Version number 2 Ref SOP/CLN/001/2
More informationPolicy Flowchart. Policy Title: Research Governance, Conduct and Management Policy. Reference and Version No: IG6 Version 5
Policy Title: Research Governance, Conduct and Management Policy Reference and Version No: IG6 Version 5 Author and Job Title: J Greenaway Research and Development Manager Executive Lead Medical Director
More informationGuidance Notes for Applicants of the Certificate for Clinical Trial on Medical Device
Guidance Notes for Applicants of the Certificate for Clinical Trial on Medical Device List of Contents Page 1. Introduction 1.1 The Medical Device Administrative Control System and the 3 proposed legislation
More informationSUBJECT ACCESS REQUEST PROCEDURE
SUBJECT ACCESS REQUEST PROCEDURE Document History Document Reference: Document Purpose: IG31 This procedure sets out the responsibility for staff when receiving requests for information provided under
More informationRD SOP17 Research data management and security
RD SOP17 Research data management and security Version Number: V2 Name of originator/author: Dr Andy Mee, R&I Manager Name of responsible committee: R&I Committee Name of executive lead: Medical Director
More informationEssentials of RESEARCH GOVERNANCE
Promoting Good Practice in Research Essentials of RESEARCH GOVERNANCE Information for Researchers, Students and Support Staff involved in Health & Social Care Research 2005 Reproduced with the permission
More informationThis SOP may also be used by staff from other NHS areas, or organisations, with prior agreement.
Standard Operating Procedure: SOP Number: SOP-QA-32 Version No: 1 Author: Date: (Gary Cooper, Named Sponsor Archivist, NHS Grampian and University of Aberdeen) 1-9-15 Approved by: Date: 1-9-15 (Professor
More informationComplaints Policy. Complaints Policy. Page 1
Complaints Policy Page 1 Complaints Policy Policy ref no: CCG 006/14 Author (inc job Kat Tucker Complaints & FOI Manager title) Date Approved 25 November 2014 Approved by CCG Governing Body Date of next
More informationRESEARCH GOVERNANCE POLICY
RESEARCH GOVERNANCE POLICY Policy Title Version: Approved by: Date of approval: 29 June 2015 Policy supersedes: Lead Board Director: Policy Lead (and author if different): Name of responsible committee/group:
More informationJRO RMG RSS SOP 12. Standard Operating Procedure (SOP) for Study Closedown and Archiving Royal Free site specific SOP
Office Location: 1 st Floor Maple House 149 Tottenham Court Road London W1T 7DN Joint Research Office Tel No. 0845 1555 000 Web-sites: www.uclh.nhs.uk; www.ucl.ac.uk/jro Postal Address: UCL, Gower Street
More informationTrial Delivery SOP 05 Trial Archiving
Gloucestershire Research and Development Consortium Standard Operating Procedure R&D SOP TD 05Trial Archiving Trial Delivery SOP 05 Trial Archiving IT IS THE RESPONSIBILITY OF ALL USERS OF THIS SOP TO
More informationNHS Commissioning Board: Information governance policy
NHS Commissioning Board: Information governance policy DOCUMENT STATUS: To be approved / Approved DOCUMENT RATIFIED BY: DATE ISSUED: October 2012 DATE TO BE REVIEWED: April 2013 2 AMENDMENT HISTORY: VERSION
More informationGuidance notes on collection of drug safety information by employees and agents of pharmaceutical companies
Guidance notes on collection of drug safety information by employees and agents of pharmaceutical companies March 2013 Guidance notes on collection of drug safety information by employees and agents of
More informationClaims Management Policy. Director of Corporate Affairs and Communications. First Issued On: 31 March 2009 (version 1.000)
Title: Reference No: Owner: Author: Claims Management Policy NYYPCT/COR/02 Director of Corporate Affairs and Communications Steve Mason, Legal Services Manager First Issued On: 31 March 2009 (version 1.000)
More informationClaims Management Policy
Claims Management Policy April 2015 Author: Responsibility: Janet Young, Governance & Risk Manager All Staff should adhere to this policy Effective Date: April 2015 Review Date: April 2017 Reviewing/Endorsing
More informationDrinking Water Quality Management Plan Review and Audit Guideline
Drinking Water Quality Management Plan Review and Audit Guideline This publication has been compiled by Queensland Water Supply Regulator, Department of Energy and Water Supply. State of Queensland, 2013.
More informationSubject Access Request Policy
Trust Policy Subject Access Request Policy Department / Service: Corporate Originator: Company Secretary Accountable Director: Director of Nursing Approved by: Information Governance Steering Group Trust
More informationResearch & Development Directorate
Research & Development Directorate Type of Document Standard Operating Procedure Name SOP10: Routine Audit Version 3.0 Author Miss Jennifer Boyle (Research Governance Co-ordinator) Version Superseded 2.4
More informationSubject Access Request (SAR) Procedure
Subject Access Request (SAR) Procedure East and North Hertfordshire Clinical Commissioning Group Page 1 of 16 DOCUMENT CONTROL SHEET Document Owner: Chief Finance Officer Document Author(s): Anne Ephgrave
More informationRECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING
RECOMMENDATION ON THE CONTENT OF THE TRIAL MASTER FILE AND ARCHIVING July 2006 TABLE OF CONTENTS Page 1. Introduction 2 2. Scope 2 3. Documents to be archived 2 4. Quality of essential documents 10 5.
More informationIntroduction 2. 1. The Role of Pharmacy Within a NHS Trust 3. 2. Pharmacy Staff 4. 3. Pharmacy Facilities 5. 4. Pharmacy and Resources 6
Index Index Section Page Introduction 2 1. The Role of Pharmacy Within a NHS Trust 3 2. Pharmacy Staff 4 3. Pharmacy Facilities 5 4. Pharmacy and Resources 6 5. Prescription Charges 7 6. Communication
More informationEU Clinical Trials Regulation Regulation EU 536/2014
EU Clinical Trials Regulation Regulation EU 536/2014 María Jesús Zafra Director, QA & Compliance Table of contents 1 2 3 4 Introduction Timelines and main changes Highlights 5 Impact on company processes
More informationIntellectual Property Management Policy
Intellectual Property Management Policy Executive or Associate Director lead Policy author/ lead Feedback on implementation to Clive Clarke Ken Lawrie/Karen Robinson Business Planning Group Date of draft
More informationA New Standard for Medical Device Adverse Event Classification
Vol. 5, No. 12, December 2009 Can You Handle the Truth? A New Standard for Medical Device Adverse Event Classification By Nancy J. Stark Adverse events are defined and managed differently in the device
More informationGood Clinical Practice (GCP)
Good Clinical Practice (GCP) Joanne Thompson Clinical Trials Monitor and Trainer, UHL Dec 2011 1 1 What is GCP? An international ethical and scientific quality standard for designing, conducting, recording
More informationClinical Trials and Safety Surveillance of Drugs in Development
Clinical Trials and Safety Surveillance of Drugs in Development Hoda Eid, M.Sc., Ph.D. Manager, ADR Unit Office of Clinical Trials Therapeutic Products Directorate hoda_eid@hc-sc.gc.ca Overview Clinical
More informationEssential Documentation and the Creation and Maintenance of Trial Master Files
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationTopics for today. Issues: Regulatory Obligations Post-marketing Adverse Event Reporting; MDRs and Safety Reports. Post-marketing Submissions
Issues: Regulatory Obligations Post-marketing Adverse Event Reporting; MDRs and Safety Reports Martha A. Feldman, RAC Drug & Device Development Co., Inc. Topics for today Post-approval requirements for
More informationEffective Date: October 2015
University of Maryland Greenebaum Cancer Center UMGCC Standard Operating Procedure Title: Data & Safety Monitoring Plan Effective Date: October 2015 Procedure No: DSM001 University of Maryland Greenebaum
More informationQUALITY SYSTEM REQUIREMENTS FOR PHARMACEUTICAL INSPECTORATES
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 002-3 25 September 2007 RECOMMENDATION ON QUALITY SYSTEM REQUIREMENTS FOR PHARMACEUTICAL INSPECTORATES PIC/S September
More informationNursing Agencies. Minimum Standards
Nursing Agencies Minimum Standards 1 Contents Page Introduction 3 Values underpinning the standards 6 SECTION 1 - MINIMUM STANDARDS Management of the nursing agency 1. Management and control of operations
More informationAll CCG staff. This policy is due for review on the latest date shown above. After this date, policy and process documents may become invalid.
Policy Type Information Governance Corporate Standing Operating Procedure Human Resources X Policy Name CCG IG03 Information Governance & Information Risk Policy Status Committee approved by Final Governance,
More informationIS INFORMATION SECURITY POLICY
IS INFORMATION SECURITY POLICY Version: Version 1.0 Ratified by: Trust Executive Committee Approved by responsible committee(s) IS Business Continuity and Security Group Name/title of originator/policy
More informationHealth Products and Food Branch. www.hc-sc.gc.ca
Health Products and Food Branch 1 HEALTH CANADA PART C DIVISION 5 - DRUGS FOR CLINICAL TRIALS INVOLVING HUMAN SUBJECTS Part C - Division 5 2 Part A: Part B: Part C: Part D: Part E: Part G: Part J: Administration
More informationThe role, duties and responsibilities of clinical trials personnel Monitoring: rules and recommendations
The role, duties and responsibilities of clinical trials personnel Monitoring: rules and recommendations Maria Luisa Paoloni OPBG Clinical & Research Services Monitoring and Responsible of monitoring:
More informationOECD Recommendation on the Governance of Clinical Trials
OECD Recommendation on the Governance of Clinical Trials Marketing authorisation status of the medicinal products Non-authorised medicine Authorised medicine, treatment regimen outside
More informationTANZANIA FOOD AND DRUGS AUTHORITY GUIDELINES FOR INSURANCE AND INDEMNITY OF CLINICAL TRIALS IN TANZANIA
Doc. No. TFDA/DMC/G/CT/003 TANZANIA FOOD AND DRUGS AUTHORITY GUIDELINES FOR INSURANCE AND INDEMNITY OF CLINICAL TRIALS IN TANZANIA (Made under Section 67 (b) of the Tanzania Food, Drugs and Cosmetics Act,
More informationCONTROLLED DOCUMENT. Uncontrolled Copy. RDS014 Research Related Archiving. University Hospitals Birmingham NHS Foundation Trust
University Hospitals Birmingham NHS Foundation Trust CONTROLLED DOCUMENT RDS014 Research Related Archiving CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Version Number: 1 Controlled Document
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2012) Sweden
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe Sweden Question 1: What laws or regulations apply to an application for conducting a clinical trial in Sweden?
More informationData Management in Clinical Trials
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research February 19, 2013 Diane St. Germain, RN, MS Nurse Consultant Division of Cancer Prevention National Cancer
More information